The invasive front in endometrial carcinoma: Higher proliferation and associated derailment of cell cycle regulators
Abstract
The aim of the study was to explore whether expression of proliferation and hypoxia-related proteins differs in the central parts and the invasive front in endometrial carcinomas. Proliferation-associated proteins Ki67 and cyclin A; cell cycle regulators p16, p21, p53, cyclin D1, cyclin E, and cdk2; and hypoxia-inducible factor 1alpha and its downstream factors glucose transporter 1, carbonic anhydrase IX, and vascular endothelial growth factor were immunohistochemically stained in paraffin-embedded specimens from endometrioid (n = 33), mucinous (n = 1), and serous (n = 5) endometrial carcinomas. The percentages of positive cells at the invasive front and central tumor parts were scored and compared. Ki67 (P < .001), cyclin E (P = .018), p16 (P = .003), and cdk2 (.001) were expressed higher at the invasive front than centrally (Wilcoxon signed ranks test). Higher expression of these antigens at the invasive front was seen in 31 of 38 cases for Ki67, in 16 of 39 cases for cyclin E, in 15 of 39 cases for cdk2, and in 11 of 39 cases for p16. The other cell cycle proteins and the hypoxia-related factors did not show significant differences in expression between the central parts and the invasive front. Endometrial carcinomas clearly show an invasive front that is characterized by higher proliferation and progressive derailment of the cell cycle regulators cyclin E, p16, and cdk2, but not by an increased hypoxic response.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In colon and endometrial cancers, senescence markers are linked to improved prognosis.
“Colon and endometrial cancers have also been studied, as well as senescence markers linked to improved prognosis [44,45].”
From Senescence and Cancer: A Review of Clinical Implications of Senescence and Senotherapies (2020) · cites this paper as [45]
The citation lists haven’t been fetched yet
References 41 · Cited by 53
- Authors
- Horrée, N., van Diest, P. J., Sie-Go, D. M. D. S., & Heintz, A. P. M.
- Affiliations
- University Medical Center Utrecht (NL)
- Venue
- Human Pathology
- Publisher
- Elsevier BV
- Published
- 2007-08
- Volume
- 38
- Issue
- 8
- Pages
- 1232-1238
- ISSN
- 0046-8177 (ISSN-L)
- OpenAlex
- W1983818525
- Cited by
- 53
- References
- 41
- Citations by year
- 2026: 1 · 2025: 3 · 2024: 2 · 2022: 4 · 2021: 3 · 2020: 4 · 2019: 4 · 2017: 2 · 2016: 8 · 2015: 2 · 2014: 1 · 2013: 3 · 2012: 2
- FWCI
- 4.28
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Human Pathology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Obstetrics and Gynecology › Endometrial and Cervical Cancer Treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
- Health Sciences › Medicine › Reproductive Medicine › Ovarian cancer diagnosis and treatment
- Keywords
- endometrial cancer, tumor invasion, invasion front, cell proliferation, Ki-67, cyclin E, p16, CDK2, cell cycle regulators, hypoxia, hypoxia-inducible factor-1α, carbonic anhydrase IX, vascular endothelial growth factor, glucose transporter 1, endometrioid carcinoma, serous carcinoma, mucinous carcinoma
- MeSH terms
- Adenocarcinoma, Mucinous, Cell Count, Female, Humans, Immunoenzyme Techniques, Myometrium, Neoplasm Invasiveness, Biomarkers, Tumor, Endometrial Neoplasms, Carcinoma, Endometrioid, Cystadenocarcinoma, Serous, Cell Cycle Proteins, Ki-67 Antigen, Cyclin A, Cell Proliferation
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review